Business Wire

COTY

21.4.2021 10:02:12 CEST | Business Wire | Press release

Share
Coty Lands Industry First With Sustainability Certificate for Lancaster Sun Care Products

Coty Inc. (NYSE: COTY), one of the world’s leading beauty companies and the global leader in fragrances, today announced that Lancaster has become the first ever sun care brand awarded the prestigious C2C Certified Material Health Certificate at the Silver level from the Cradle to Cradle Products Innovation Institute.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005237/en/

The award indicates that 100% of the ingredients in Lancaster Sun Sensitive collection –Lancaster’s first clean and vegan range, and its most environmentally friendly yet - meet the Institute’s strict criteria. In addition to recognizing the sustainable innovation behind the collection, the Certification serves as the foundation for further improving the sustainability and product safety of sun care products over time.

Lancaster Sun Sensitive collection provides broad sun protection* targeting 100% of sun spectrum through a clean, minimalistic** vegan formula providing even sensitive skin with a delicate golden glow, preserved from redness and discomfort. The products also feature an ocean friendly UV filter system*** - all delivered in eco-designed packaging.****

Sue Y. Nabi, Chief Executive Officer at Coty , said: “Sustainability is the ultimate driver of innovation and brands like Lancaster are creating outstanding products that are truly clean and green. Today’s consumer rightly expects that their favorite products also deliver when it comes to environmental performance. It’s our approach to product innovation that sets Coty apart and these industry firsts reflect the expertise of our teams and our brands.”

The C2C Certified Material Health Certificate by the Cradle to Cradle Products Innovation Institute offers a solution to growing industry and consumer interest in knowing more about the chemicals used in products across their supply chains and avoiding chemicals of concern. By using the rigorous, globally recognized material health assessment methodology of the Cradle to Cradle Certified Product Standard, the Material Health Certificate provides manufacturers with a trusted means of assessing, optimizing and verifying their product chemistries for safety and the environment. A C2C Certified Material Health Certificate is awarded to products that meet the Material Health requirements of the multi-attribute Cradle to Cradle Certified™ Product Standard. The certificate is valid for two years.

Beyond leading the way in sun care with the first C2C Certified Material Health Certificate in the category, Coty is also paving the way towards greater product safety, transparency and innovation throughout the beauty industry ,” said Dr. Christina Raab, Vice President of Strategy and Development for the Cradle to Cradle Products Innovation Institute.

Laure Calvel, VP Global Marketing at Lancaster , said: Receiving the Cradle to Cradle Products Innovation Institute’s Silver Level Material Health Certificate for our Sun Sensitive range is another positive step in demonstrating the safe use of materials that are circular and responsible in our products. We have a framework for improving the sustainability of all the products in our portfolio and very ambitious plans over the coming years.”

Product innovation is a crucial element of Coty’s journey to becoming a more circular business and creating a more sustainable and inclusive world – as set out in its Beauty That Lasts’ strategy. Today’s announcement builds on the success of Calvin Klein’s first clean and environmentally conscious fragrance, CK EVERYONE, which achieved a Material Health Certificate at the Silver level from the Cradle to Cradle Products Innovation Institute in April 2020.

Last month, Coty announced a partnership with LanzaTech to introduce sustainable ethanol made from captured-carbon emissions into its fragrance products. LanzaTech captures industrial emissions and processes the waste gases into a new, more sustainable source of ethanol that is suitable for use in fragrances. Coty has set the goal of having the majority of its fragrance portfolio using ethanol sourced from carbon-capture by 2023.

* No sunscreen product can provide full protection against sun’s rays. Overexposure to the sun is a dangerous health risk.
** Formulas contain on average 40% fewer ingredients than previous range/competitors.
*** In vitro test method established with the University of Nice Institute to assess the potential impact of a sunscreen product on cnidarian cells.
**** Tubes/bottles contain at minimum 50% post-consumer recycled materials.

About Coty Inc.

Coty is one of the world’s largest beauty companies with an iconic portfolio of brands across fragrance, color cosmetics, and skin and body care. Coty is the global leader in fragrance and number three in color cosmetics. Coty’s products are sold in over 150 countries around the world. Coty and its brands are committed to a range of social causes as well as seeking to minimize its impact on the environment. For additional information about Coty Inc., please visit www.coty.com .

About the Cradle to Cradle Products Innovation Institute

The Cradle to Cradle Products Innovation Institute is dedicated to powering innovation for the circular economy through products that have a positive impact on people and planet. Through the Cradle to Cradle Certified® Products Program, the Institute sets the global standard for products that are safe, circular and made responsibly. Cradle to Cradle Certified is used by many future-focused designers, brands, retailers and manufacturers across the value chain to innovate and optimize materials and products according to the world’s most advanced science-based measures for material health, product circularity, renewable energy and climate, water and soil stewardship, and social fairness. The Institute also powers the global shift to a circular economy through partnerships and collaborative initiatives that equip businesses, governments and other stakeholders with the technical solutions and knowledge they need to innovate the way products are designed and made. For more information about the Institute, visit c2ccertified.org. C2C Certified Material Health Certificate™ is a word mark licensed by the Cradle to Cradle Products Innovation Institute.

About Lancaster SUN SENSITIVE

Lancaster’s broadest sun protection respects the most sensitive skin’s needs:

  • Provides optimal protection with Full Light Technology, which targets 100% of sun spectrum (1) (UVB, UVA, Visible Light and Infrared rays).
  • Gives a luminous and long-lasting tan which develops gradually thanks to the exclusive natural origin Tan Activator Complex, which stimulates the natural tanning process for a never-ending summer.
  • Helps reduce redness and the feeling of discomfort while protecting sensitive skin from sun damage, thanks to the new natural origin Sunsicalm complex.
  • Respects marine life, with an ocean friendly UV filter system and water-resistant formulas, while being respectful for the skin with minimalistic (2), vegan formulas, all in eco-designed packaging (3).
  • Provides ultra-sensorial and lightweight textures yet clean, that penetrates easily without leaving white traces with a transparent finish after application and a clean labelled fragrance.
  • For children, a convenient face and body spray that meets all their needs (anti-sand, wet skin application, tearless formula, water resistant and fragrance-free).
  1. No sunscreen product can provide full protection against sun’s rays. Overexposure to the sun is a dangerous health risk.
  2. Formulas contain on average 40% fewer ingredients than previous range/competitors.
  3. Tubes/bottles contain at minimum 50% post-consumer recycled materials.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye